Keenova Study Suggests XIAFLEX as Nonsurgical Option for Dupuytren Recurrence

Event summary

  • Keenova published a retrospective analysis of XIAFLEX in the Journal of Hand Surgery Global Online on March 3, 2026.
  • The study evaluated XIAFLEX for treating Dupuytren contracture recurrence after surgery in 10 U.S. clinical centers.
  • Primary endpoints measured joint contracture changes within 12 months of treatment.
  • Adverse events were consistent with prior reports of collagenase clostridium histolyticum (CCH).
  • Dupuytren contracture affects an estimated 13 million Americans.

The big picture

Keenova's study provides new evidence supporting XIAFLEX as a nonsurgical alternative for Dupuytren contracture recurrence, addressing a significant unmet need in hand surgery. The findings could expand XIAFLEX's clinical utility, particularly as healthcare providers seek to avoid repeat surgeries. This aligns with broader trends in orthopedic care toward minimally invasive treatments and personalized medicine.

What we're watching

Clinical Adoption
How hand specialists will integrate XIAFLEX into recurrence management protocols.
Regulatory Scrutiny
Whether the study's findings will prompt further evaluations of XIAFLEX's safety profile.
Market Positioning
The pace at which Keenova can leverage this data to differentiate XIAFLEX in the Dupuytren treatment landscape.